Recruiting
Trials by recruitment status
Public Title | Date of registration | Sponsor |
---|---|---|
Phase II / III. Nimotuzumab in patients with triple-negative breast cancer. | 23/05/2014 | CIM |
SOBERANA PEDIATRIA CLINICA 1 | 23/07/2021 | FINLAY |
Itolizumab (T1h) combined with insulin in patients with Type I Diabetes Mellitus | 23/12/2016 | CIM |
SURFACEN in ARDS. Adults. Phase IV | 24/06/2015 | CENSA |
Stem cell assisted centrifugal fat transfer | 26/03/2021 | HHA |
Racotumomab,Nimotuzumab or Docetaxel in the treatment of the advanced non-small cell lung cancer. | 26/05/2014 | CIM |
Evaluation of Clinical Performance of INFANTIX in a Maternity Hospital | 27/04/2022 | CNEURO |
Predictor of response with CIMAvax EGF© in NSCLC Phase III | 29/01/2016 | CIM |
Heberon Alfa R in COVID-19 | 29/05/2020 | MINSAP_AM |
Safety and effectiveness of SURFACEN® combined with the conventional therapy, in the treatment of ARDS in pediatrics. National extension | 29/09/2017 | CENSA |
Nimotuzumab-pancreatic cancer-adults-Phase IV. | 30/04/2017 | CIM |
Treatment for maxillary cysts | 30/05/2018 | SSA |
- « first
- ‹ previous
- 1
- 2
- 3
- 4